{"id":4826,"date":"2024-04-17T13:05:00","date_gmt":"2024-04-17T17:05:00","guid":{"rendered":"https:\/\/stillcoviding.ca\/fr\/?p=4826"},"modified":"2024-04-17T13:41:26","modified_gmt":"2024-04-17T17:41:26","slug":"remdesivir-tied-to-25-lower-risk-of-in-hospital-death-in-adults-with-covid-and-no-added-oxygen","status":"publish","type":"post","link":"https:\/\/stillcoviding.ca\/fr\/nouvelles\/remdesivir-tied-to-25-lower-risk-of-in-hospital-death-in-adults-with-covid-and-no-added-oxygen\/","title":{"rendered":"Remdesivir tied to 25% lower risk of in-hospital death in adults with COVID and no added oxygen"},"content":{"rendered":"<p>Le m\u00e9dicament antiviral remdesivir a r\u00e9duit les taux de mortalit\u00e9 de 17&nbsp;% \u00e0 25&nbsp;% chez les adultes hospitalis\u00e9s pour la COVID-19 qui n\u2019avaient pas besoin d\u2019oxyg\u00e8ne d\u2019appoint \u00e0 l\u2019admission, sugg\u00e8re un grand <a href=\"https:\/\/academic.oup.com\/ofid\/advance-article\/doi\/10.1093\/ofid\/ofae202\/7646755\" lang=\"en\" target=\"_blank\" rel=\"noopener\">\u00e9tude<\/a> publi\u00e9e hier dans <em>Open Forum Infectious Diseases<\/em>. <\/p>\n<p>L\u2019\u00e9tude, men\u00e9e par des chercheurs du d\u00e9veloppeur de remdesivir (Veklury), Gilead Sciences, a utilis\u00e9 une base de donn\u00e9es multicentrique de facturation hospitali\u00e8re am\u00e9ricaine pour comparer les taux de d\u00e9c\u00e8s \u00e0 l\u2019h\u00f4pital parmi 58&nbsp;188 patients \u00e0 l\u2019air ambiant qui ont re\u00e7u au moins une dose de remdesivir dans les deux premiers jours de leur admission \u00e0 l\u2019h\u00f4pital et 17&nbsp;574 patients appari\u00e9s n\u2019ayant pas re\u00e7u le m\u00e9dicament. Le m\u00e9dicament est le plus efficace lorsqu\u2019il est administr\u00e9 t\u00f4t dans l\u2019infection, lorsque la r\u00e9plication virale est la plus active.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le m\u00e9dicament antiviral remdesivir a r\u00e9duit les taux de mortalit\u00e9 de 17&nbsp;% \u00e0 25&nbsp;% chez les adultes hospitalis\u00e9s pour la COVID-19 qui n\u2019avaient pas besoin d\u2019oxyg\u00e8ne d\u2019appoint \u00e0 l\u2019admission, sugg\u00e8re un grand <a href=\"https:\/\/academic.oup.com\/ofid\/advance-article\/doi\/10.1093\/ofid\/ofae202\/7646755\" lang=\"en\" target=\"_blank\" rel=\"noopener\">\u00e9tude<\/a> publi\u00e9e hier dans <em>Open Forum Infectious Diseases<\/em>. <\/p>\n<p>L\u2019\u00e9tude, men\u00e9e par des chercheurs du d\u00e9veloppeur de remdesivir (Veklury), Gilead Sciences, a utilis\u00e9 une base de donn\u00e9es multicentrique de facturation hospitali\u00e8re am\u00e9ricaine pour comparer les taux de d\u00e9c\u00e8s \u00e0 l\u2019h\u00f4pital parmi 58&nbsp;188 patients \u00e0 l\u2019air ambiant qui ont re\u00e7u au moins une dose de remdesivir dans les deux premiers jours de leur admission \u00e0 l\u2019h\u00f4pital et 17&nbsp;574 patients appari\u00e9s n\u2019ayant pas re\u00e7u le m\u00e9dicament. Le m\u00e9dicament est le plus efficace lorsqu\u2019il est administr\u00e9 t\u00f4t dans l\u2019infection, lorsque la r\u00e9plication virale est la plus active.<\/p>\n<div class=\"more-link-wrapper\"><a class=\"more-link\" href=\"https:\/\/stillcoviding.ca\/fr\/nouvelles\/remdesivir-tied-to-25-lower-risk-of-in-hospital-death-in-adults-with-covid-and-no-added-oxygen\/\">Lire la suite<span class=\"screen-reader-text\">Remdesivir tied to 25% lower risk of in-hospital death in adults with COVID and no added oxygen<\/span><\/a><\/div>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[16,50,1098,486,7,558,12],"class_list":["post-4826","post","type-post","status-publish","format-standard","hentry","category-nouvelles","tag-covid-19","tag-etats-unis","tag-gilead-sciences","tag-medicaments-antiviraux","tag-recherche","tag-remdesivir","tag-sras-cov-2","entry"],"_links":{"self":[{"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/posts\/4826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/comments?post=4826"}],"version-history":[{"count":3,"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/posts\/4826\/revisions"}],"predecessor-version":[{"id":4829,"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/posts\/4826\/revisions\/4829"}],"wp:attachment":[{"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/media?parent=4826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/categories?post=4826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stillcoviding.ca\/fr\/wp-json\/wp\/v2\/tags?post=4826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}